Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL-HiChemo
NCT04459416Phase 3Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2020
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Number of Patients Using Opioids at a Given Time at Day 90 and Symptom Burden at Day 90. Started Jun 2020; status: active, not recruiting.
Beyond the preview
Go deeper on NCT04459416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459416.